ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $256M invested in Adaptimmune Therapeutics in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.27% more ownership
Funds ownership: 10.68% → 10.94% (+0.27%)
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
80
Holding in Top 10
1
Calls
$379K
Puts
$124K
Top Buyers
| 1 | +$43.3M | |
| 2 | +$1.01M | |
| 3 | +$607K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$401K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$272K |
Top Sellers
| 1 | -$5.59M | |
| 2 | -$4.99M | |
| 3 | -$4.65M | |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$2.22M |
| 5 |
SP
Syncona Portfolio
St Peter Port,
Guernsey
|
-$1.09M |